No Data
No Data
Xinbang Pharmaceuticals: 2024 Semi-Annual Report Summary
Xinbang Pharmaceuticals: 2024 Semi-Annual Report
Guizhou Xinbang Pharmaceutical (002390.SZ) released its semi-annual performance, with a net income of 0.115 billion yuan, a decrease of 26.37%.
Guizhou Xinbang Pharmaceutical (002390.SZ) released its 2024 interim report. During the reporting period, the company achieved revenue...
Declining Stock and Decent Financials: Is The Market Wrong About Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390)?
Guizhou Xinbang Pharmaceutical (002390.SZ): Its hospitals have testing services such as lymphocyte subgroups, cell apoptosis, and leukemia immunity analysis.
Guizhou Xinbang Pharmaceutical (002390.SZ) stated on the investor interactive platform that its hospital provides services such as detection of lymphocyte subgroups, lymphocyte activation, dendritic cells, cell apoptosis, and leukemia immune analysis.
Guizhou Xinbang Pharmaceutical (002390.SZ): Subsidiary pharmaceutical distribution companies have not yet engaged in self-driving delivery business.
Guizhou Xinbang Pharmaceutical (002390.SZ) stated on the investor interaction platform on July 18 that its pharmaceutical distribution subsidiary has not yet engaged in self-driving delivery business.
No Data
No Data